




MDH-111 for the Treatment of Intractable Respiratory Disease

MDH-111 (*Micrococcus luteus* EV) is a new class of first-in-class inhalational therapeutic indicated for intractable respiratory diseases, such as neutrophilic asthma, COPD, cystic fibrosis (CF), and more

MDH-111

- Naïve (natural) EVs from a single **Micrococcus** strain



Value Propositions

1. **First-in-class**: a new modality drug with a novel mechanism of action (MoA)
2. **Very safe**: a safe soil bacterium *Micrococcus luteus*-derived EVs
3. **Effective**: a disease-modifying therapy against intractable respiratory diseases, including neutrophilic asthma and COPD
4. **Convenient administration**: delivered via inhalation
5. **Affordable**: cost effective production

MDH-111: Key Indications & Development Timeline

Key Indications

- 1) **Neutrophilic (non-eosinophilic) asthma**
- 2) **Chronic obstructive pulmonary disease (COPD)**
- 3) Cystic fibrosis (CF)
- 4) Idiopathic pulmonary fibrosis (IPF)

Core patents

1. Core patent (1)
 - ✓ PCT (KR2019/002341) application date at 27/Feb/2019
 - ✓ Registered at KR, US, & pending at EP, JP, CN (as of July 2022)
2. Core patent (2)
 - ✓ PCT (KR2021/015764) application date at 03/Nov/2021

Development Timeline

IND filing ('23)



P1a ('24)



P1b ('25)



P2 ('27)



Exit